Loading
CHM-029 is an experimental small molecule from CHARM Therapeutics, in phase 1 trials for relapsed or refractory acute myeloid leukaemia with NPM1 mutation, KMT2A rearrangement or NUP98 rearrangement.
CHM-029 is a small molecule (oral) from CHARM Therapeutics. A menin inhibitor designed to closely mimic the binding of KMT2A to menin; the company reports preclinical activity against all publicly described menin resistance mutations. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia with NPM1 mutation, KMT2A rearrangement or NUP98 rearrangement. ClinicalTrials.gov registers it in one study linked below. CHARM calls the trial phase 1/2; ClinicalTrials.gov registers NCT07751991 as phase 1, recruiting. The company announced on 7 October 2026 that dosing had begun and that it expects initial data in 2027. Whether it works in people has not been established unless a trial below reports it.
A menin inhibitor designed to closely mimic the binding of KMT2A to menin; the company reports preclinical activity against all publicly described menin resistance mutations. Connects to Menin.
1.CHM-029 slips into a pocket on Menin.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CHM-029" OR ABSTRACT:"CHM-029") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CHM-029, not a curated reading list.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/